Bezalip (Bezafibrate): Uses, Dosage & Side Effects
A fibrate medication used to lower elevated triglycerides and cholesterol when diet and lifestyle changes alone are not enough
Bezalip (bezafibrate) is a prescription fibrate medication used to lower elevated blood lipids, particularly triglycerides and LDL cholesterol, while raising levels of protective HDL cholesterol. It belongs to the fibrate class of lipid-regulating drugs and works by activating peroxisome proliferator-activated receptors (PPARs) in the liver, which reduces triglyceride production and promotes the breakdown of lipid-rich particles in the blood. Bezalip is used alongside dietary measures, exercise, and weight management when these lifestyle changes alone are not sufficient to achieve healthy lipid levels.
Quick Facts: Bezalip
Key Takeaways
- Bezalip (bezafibrate) is a fibrate medication primarily used to lower elevated triglycerides and improve overall blood lipid profiles, working alongside dietary and lifestyle modifications.
- It activates PPAR receptors in the liver, which can reduce triglycerides by 30-50% and raise HDL cholesterol by 10-20%, with modest LDL-lowering effects as well.
- Bezalip should not be used in patients with severe liver or kidney disease, those on dialysis, or anyone with a history of photosensitivity reactions to fibrates.
- Combining Bezalip with statins requires careful medical supervision due to an increased risk of myopathy and rhabdomyolysis; report any unexplained muscle pain immediately.
- Available as Bezalip 200 mg (taken three times daily) or Bezalip Retard 400 mg (once daily modified-release), both taken with meals.
What Is Bezalip and What Is It Used For?
Bezalip belongs to a group of medicines called fibrates (fibric acid derivatives), which are among the most effective medications for lowering triglyceride levels in the blood. The active substance, bezafibrate, was first introduced into clinical practice in the 1970s and has been used extensively in Europe and other regions for the management of various forms of dyslipidaemia, particularly conditions characterized by elevated triglycerides.
Elevated blood lipids, including high levels of low-density lipoprotein (LDL) cholesterol and triglycerides, are well-established risk factors for the development of atherosclerosis — the progressive narrowing and hardening of arteries. Atherosclerosis is the underlying cause of coronary heart disease, angina pectoris (chest pain), myocardial infarction (heart attack), peripheral arterial disease, and ischaemic stroke. The risk is compounded when combined with other cardiovascular risk factors such as smoking, hypertension (high blood pressure), diabetes mellitus, obesity, and a sedentary lifestyle.
Bezafibrate works primarily by activating peroxisome proliferator-activated receptors (PPARs), particularly PPAR-alpha, in the liver and other tissues. Unlike most other fibrates, bezafibrate has been described as a "pan-PPAR agonist" because it also activates PPAR-gamma and PPAR-delta, albeit to a lesser extent. This broad PPAR activation results in multiple beneficial effects on lipid metabolism: it increases the activity of lipoprotein lipase (the enzyme responsible for breaking down triglyceride-rich lipoproteins), enhances hepatic fatty acid oxidation, and reduces hepatic very-low-density lipoprotein (VLDL) secretion. The net clinical effect is a significant reduction in plasma triglyceride levels (typically 30-50%), a moderate reduction in LDL cholesterol, and a clinically meaningful increase in HDL (high-density lipoprotein) cholesterol by approximately 10-20%.
Bezalip is used in conjunction with dietary measures (such as a heart-healthy, low-fat diet), regular physical exercise, weight management, and other non-pharmacological treatments to lower blood lipid levels. It is not a substitute for lifestyle modifications; rather, it is prescribed when these measures alone are insufficient to bring lipid levels within recommended targets. In clinical practice, bezafibrate is most commonly used for the treatment of hypertriglyceridaemia (elevated triglycerides), mixed dyslipidaemia (elevated triglycerides combined with elevated cholesterol), type III hyperlipoproteinaemia, and secondary dyslipidaemia associated with diabetes mellitus or metabolic syndrome.
The European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) guidelines on dyslipidaemia management recommend fibrates as an option for patients with elevated triglycerides (above 2.3 mmol/L or 200 mg/dL), particularly when triglyceride-rich lipoproteins contribute significantly to residual cardiovascular risk despite statin therapy. The Bezafibrate Infarction Prevention (BIP) trial and other clinical studies have demonstrated that bezafibrate is particularly beneficial in patients with features of the metabolic syndrome, including elevated triglycerides and low HDL cholesterol.
What Should You Know Before Taking Bezalip?
Contraindications
There are specific medical situations in which Bezalip must not be used. Understanding these contraindications is essential before starting treatment with this medication. You should not take Bezalip if any of the following apply to you:
- Allergy to bezafibrate or other fibrates: If you have ever had an allergic reaction (hypersensitivity) to bezafibrate, any other fibrate medication (such as gemfibrozil, fenofibrate, or ciprofibrate), or any of the inactive ingredients listed in the product information, you must not take this medication.
- Severe liver disease: Patients with significant hepatic impairment should not use bezafibrate, as the drug is metabolized by the liver and may accumulate to toxic levels in patients with severely compromised hepatic function.
- Severe kidney disease: Bezafibrate is primarily excreted by the kidneys. Patients with severe renal impairment (creatinine clearance below 15 mL/min) or those receiving dialysis should not use this medication due to the risk of drug accumulation and increased toxicity.
- Dialysis treatment: Bezafibrate is not adequately removed by haemodialysis or peritoneal dialysis, and patients undergoing any form of dialysis must not use this medication.
- Previous photosensitivity to fibrates: If you have experienced photoallergic or phototoxic skin reactions (such as severe sunburn-like reactions) during previous treatment with any fibrate medication, you should not take Bezalip.
Warnings and Precautions
Before starting treatment with Bezalip, talk to your doctor, pharmacist, or nurse. This is especially important if you have any existing liver, kidney, or gallbladder disease, as these conditions require careful monitoring during fibrate therapy. Your doctor may need to perform blood tests to check your liver function, kidney function, and creatine kinase (CK) levels before and during treatment.
The simultaneous use of Bezalip with a statin (such as simvastatin, atorvastatin, or rosuvastatin) may increase the risk of serious muscle damage, including rhabdomyolysis. This is a rare but potentially life-threatening condition where damaged muscle tissue releases proteins into the bloodstream that can cause kidney failure. If you experience unexplained muscle pain, tenderness, weakness, or cramps while taking Bezalip, stop the medication and contact your doctor immediately.
Fibrate medications, including bezafibrate, have been associated with an increased risk of gallstone formation (cholelithiasis). This occurs because fibrates alter the composition of bile, which can promote cholesterol crystallization in the gallbladder. If you have a history of gallstones or gallbladder disease, your doctor will carefully weigh the benefits and risks of fibrate therapy. If you develop symptoms suggestive of gallstones (such as sudden, intense pain in the upper right abdomen, nausea, or vomiting), seek medical attention promptly.
Renal function should be monitored during treatment, particularly in patients with pre-existing mild to moderate renal impairment. In patients with reduced kidney function, the dose of bezafibrate may need to be reduced, and the modified-release formulation (Bezalip Retard) should generally not be used in patients with significantly impaired renal function due to the risk of accumulation.
Pregnancy and Breastfeeding
If you are pregnant, planning to become pregnant, think you may be pregnant, or are breastfeeding, consult your doctor or pharmacist before using Bezalip. There is limited clinical data on the use of bezafibrate during human pregnancy. Animal studies have not demonstrated teratogenic effects, but as a precautionary measure, bezafibrate is not recommended during pregnancy because its safety in pregnant women has not been adequately established.
It is not known whether bezafibrate or its metabolites are excreted in human breast milk. Given the lack of safety data, mothers who are being treated with Bezalip should not breastfeed. If lipid-lowering treatment is considered necessary during breastfeeding, your doctor will discuss alternative options with you.
Driving and Operating Machinery
In uncommon cases, side effects such as dizziness, fatigue, or muscle weakness may occur during treatment with Bezalip. These symptoms could impair your ability to drive vehicles or operate machinery safely. You are personally responsible for assessing whether you are fit to drive or perform tasks requiring alertness. If you experience any symptoms that might affect your ability to concentrate or react quickly, you should avoid driving or operating dangerous machinery until the symptoms resolve. Discuss any concerns with your doctor.
Bezalip tablets contain less than 1 mmol (23 mg) of sodium per tablet, meaning they are essentially sodium-free. This is relevant for patients who are on a controlled sodium diet.
How Does Bezalip Interact with Other Drugs?
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medications, including over-the-counter medicines, herbal remedies, and dietary supplements. Bezafibrate can interact with several other medications in clinically important ways, and dosage adjustments or alternative therapies may be necessary.
Major Interactions
| Medication | Interaction | Clinical Advice |
|---|---|---|
| Statins (simvastatin, atorvastatin, rosuvastatin) | Increased risk of myopathy and rhabdomyolysis (serious muscle damage) | Use combination only under close medical supervision; report any muscle pain immediately; avoid gemfibrozil-statin combinations |
| Warfarin and other oral anticoagulants | Enhanced anticoagulant effect; increased risk of bleeding | More frequent INR monitoring required; warfarin dose may need to be reduced by up to 30% |
| Cholestyramine (bile acid sequestrant) | Reduced absorption of bezafibrate when taken simultaneously | Take the medications at least 2 hours apart; take Bezalip first, then cholestyramine |
| Ciclosporin (immunosuppressant) | Potential reduction in kidney function; altered ciclosporin levels | Monitor renal function closely; dose adjustments may be needed |
Minor Interactions
| Medication | Interaction | Clinical Advice |
|---|---|---|
| Sulfonylureas (glibenclamide, glimepiride) | Enhanced blood glucose-lowering effect; increased risk of hypoglycaemia | Monitor blood glucose more frequently; sulfonylurea dose may need reduction |
| Insulin | Bezafibrate may improve insulin sensitivity, potentiating insulin's glucose-lowering effect | Monitor blood glucose closely; insulin dose may require adjustment |
| MAO inhibitors | Theoretical risk of enhanced effects; limited clinical data | Use with caution; inform your doctor of any MAO inhibitor use |
The interaction between fibrates and diabetes medications is particularly clinically relevant. Bezafibrate has been shown in clinical studies (including the BIP trial) to improve insulin sensitivity and glucose metabolism, which can potentiate the hypoglycaemic effects of both oral antidiabetic drugs and insulin. Patients with type 2 diabetes who start bezafibrate therapy should monitor their blood glucose levels more frequently during the initial weeks of treatment, and their diabetes medication dosage may need to be reduced under medical supervision.
If you take cholestyramine (a bile acid sequestrant also used to lower cholesterol), it is essential that the two medications are taken at least two hours apart. Cholestyramine can bind to bezafibrate in the gastrointestinal tract and significantly reduce its absorption, potentially rendering the fibrate therapy ineffective. As a general rule, take Bezalip first and then cholestyramine at least two hours later.
What Is the Correct Dosage of Bezalip?
Always take Bezalip exactly as your doctor or pharmacist has instructed. Do not change the dose or stop taking the medication without consulting your healthcare provider first. Your doctor will determine the appropriate dose based on your individual lipid levels, kidney function, and overall clinical condition.
Adults
Bezalip 200 mg (Immediate-Release Film-Coated Tablets)
The recommended dose is 1 tablet (200 mg) taken three times daily, preferably with or immediately after meals. Tablets should be swallowed whole with a glass of water and should not be crushed, chewed, or broken. Taking the tablets with food helps ensure optimal absorption and reduces the likelihood of gastrointestinal side effects.
Bezalip Retard 400 mg (Modified-Release Tablets)
The recommended dose is 1 tablet (400 mg) taken once daily, preferably in the morning or evening with a meal. The modified-release formulation must be swallowed whole — it must not be crushed, split, or chewed, as this would destroy the controlled-release mechanism and could result in an excessive initial dose followed by inadequate drug levels.
| Patient Group | Formulation | Dose | Notes |
|---|---|---|---|
| Adults (normal kidney function) | 200 mg tablets | 200 mg three times daily | Take with meals; swallow whole |
| Adults (normal kidney function) | 400 mg Retard | 400 mg once daily | Once daily convenience; do not crush |
| Mild renal impairment | 200 mg tablets | As directed by doctor | Dose may be reduced; regular monitoring |
| Moderate renal impairment | 200 mg tablets only | Reduced dose as per GFR | Retard formulation not recommended |
| Severe renal impairment / Dialysis | N/A | Contraindicated | Do not use Bezalip |
Children
The use of Bezalip in children and adolescents is not recommended because the safety and efficacy of bezafibrate in this age group have not been established through adequate clinical trials. Dyslipidaemia in paediatric patients is typically managed through dietary intervention, lifestyle modifications, and, when pharmacological treatment is needed, other classes of lipid-lowering drugs that have been studied in the paediatric population (such as certain statins for familial hypercholesterolaemia). If your child has been diagnosed with a lipid disorder, their treatment should be guided by a paediatric specialist.
Elderly
No specific dose adjustment is generally required for elderly patients, provided they have adequate kidney function. However, since renal function naturally declines with age, older patients are more likely to have some degree of renal impairment. Your doctor will check your kidney function through blood tests before starting treatment and at regular intervals during therapy. If kidney function is reduced, the dose may need to be lowered, and the Bezalip Retard 400 mg formulation should be used with caution or avoided. Elderly patients should also be monitored more closely for signs of myopathy (muscle problems), especially if they are also taking a statin.
Missed Dose
If you forget to take a dose of Bezalip, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one. If you frequently forget doses, consider setting an alarm or using a medication reminder tool to help you remember.
Overdose
If you take more Bezalip than prescribed, or if a child accidentally ingests the medication, contact your local poison control centre or emergency services immediately for advice. Overdose symptoms may include nausea, vomiting, and gastrointestinal discomfort. There is no specific antidote for bezafibrate overdose; treatment is symptomatic and supportive. In the hospital, gastric lavage (stomach pumping) may be considered if the overdose was recent. Bezafibrate is not effectively removed by haemodialysis.
What Are the Side Effects of Bezalip?
Like all medicines, Bezalip can cause side effects, although not everyone experiences them. Most side effects are mild to moderate and tend to improve as your body adjusts to the medication. However, some side effects can be serious and require immediate medical attention. The following sections list the known side effects of bezafibrate organized by how frequently they occur.
Unexplained muscle pain, cramps, tenderness, or weakness — these may be signs of rhabdomyolysis, a rare but serious condition (affecting up to 1 in 1,000 users). Also seek urgent care for severe skin reactions such as Stevens-Johnson syndrome (blisters or sores in the mouth, eyes, or genital area) or toxic epidermal necrolysis (widespread skin peeling). These severe skin reactions are extremely rare.
Common
May affect more than 1 in 100 people
- Gastrointestinal discomfort (stomach pain, heartburn)
- Nausea
- Loss of appetite
Uncommon
May affect up to 1 in 100 people
- Headache, dizziness
- Diarrhoea, constipation, vomiting, flatulence, abdominal pain
- Skin rash, itching (pruritus), photosensitivity, urticaria (hives)
- Liver enzyme elevation, cholestasis (bile flow obstruction), gallstones
- Muscle weakness, muscle pain (myalgia), muscle cramps
- Acute kidney injury
- Erectile dysfunction
- Hypersensitivity reactions
- Changes in laboratory values
Rare
May affect up to 1 in 1,000 people
- Hair loss (alopecia)
- Decreased white blood cell count (leukopenia) and/or red blood cell count (anaemia)
- Myositis (muscle inflammation) and rhabdomyolysis
- Pancreatitis (inflammation of the pancreas)
- Peripheral neuropathy (nerve damage), paraesthesia (tingling or numbness)
Very Rare
May affect up to 1 in 10,000 people
- Thrombocytopenia (decreased platelet count)
- Interstitial lung disease (pulmonary complications)
- Stevens-Johnson syndrome (severe allergic skin reaction)
- Toxic epidermal necrolysis (widespread skin damage)
Not Known
Frequency cannot be estimated from available data
- Depression
- Insomnia (difficulty sleeping)
The risk of muscle-related side effects (myopathy) is increased in certain patient groups, including those with renal impairment, hypothyroidism, those taking higher than recommended doses, and particularly in patients who also take statin medications. If your doctor has prescribed Bezalip together with a statin, it is especially important to report any unexplained muscle symptoms promptly.
Liver function abnormalities, including elevated transaminases (ALT and AST), have been reported in patients taking bezafibrate. These are usually reversible upon discontinuation of the medication. Your doctor will typically monitor your liver function through blood tests during the first 12 months of treatment and periodically thereafter.
If you experience any side effects not listed above, or if any of the side effects become severe or persistent, inform your doctor or pharmacist. You can also report suspected adverse reactions directly to your national pharmacovigilance authority (such as the MHRA Yellow Card scheme in the UK or the EMA EudraVigilance system in Europe) to help with the continuous monitoring of the benefit-risk balance of medicines.
How Should You Store Bezalip?
Proper storage of medications is essential to ensure that they remain safe and effective throughout their shelf life. Store Bezalip tablets at a temperature not exceeding 25°C (77°F), in the original packaging to protect from moisture and light. Do not store in the bathroom or near a kitchen sink where humidity levels are high, as moisture can degrade the tablets.
Keep this medication out of the sight and reach of children. If child-resistant packaging is available, always re-secure the closure after each use. If a child accidentally ingests Bezalip tablets, contact your local poison control centre or emergency services immediately.
Do not use Bezalip after the expiry date (EXP) printed on the outer carton and blister strips. The expiry date refers to the last day of the stated month. Using expired medication may result in reduced therapeutic effectiveness and is not recommended.
Do not dispose of medications by flushing them down the toilet or putting them in household waste. Return any unused or expired medication to your local pharmacy for safe disposal. These measures help to protect the environment and prevent accidental exposure.
What Does Bezalip Contain?
Understanding the full composition of your medication can be important, particularly if you have known allergies or intolerances to specific pharmaceutical excipients. The following information details the complete formulation of Bezalip 200 mg film-coated tablets.
Active Ingredient
The active substance is bezafibrate. Each Bezalip 200 mg film-coated tablet contains exactly 200 mg of bezafibrate. Bezafibrate is a white to off-white crystalline powder that is slightly soluble in water and freely soluble in organic solvents. Its chemical name is 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid.
Inactive Ingredients (Excipients)
The following excipients are present in the Bezalip 200 mg film-coated tablet formulation:
- Tablet core: Maize starch, pregelatinised starch, microcrystalline cellulose, sodium starch glycolate, colloidal anhydrous silica, magnesium stearate
- Film coating (Opadry): Polyvinyl alcohol, titanium dioxide (colour E171), macrogol, talc
Bezalip 200 mg tablets are white, round, film-coated tablets marked with "G6" on one side. They are available in blister packs containing 100 tablets. The tablets should appear uniform in colour and shape; do not take any tablet that appears damaged, discoloured, or shows signs of tampering.
Titanium dioxide is used as a white colouring agent in the film coating. The European Commission has re-evaluated its safety for use as a food additive, but its continued use in medicinal products as a pharmaceutical excipient has been maintained by the European Medicines Agency (EMA) on the basis that there are no suitable alternatives for certain applications and the amounts used are very small.
The modified-release formulation (Bezalip Retard 400 mg) contains 400 mg of bezafibrate with additional excipients designed to control the rate of drug release. The specific inactive ingredients may differ slightly from the 200 mg immediate-release formulation. Consult the patient information leaflet supplied with your specific product for a complete list of excipients.
Frequently Asked Questions About Bezalip
Medical References and Sources
This article is based on current medical research, regulatory documents, and international clinical guidelines. All claims are supported by scientific evidence from peer-reviewed sources.
- European Medicines Agency (EMA). "Bezafibrate - Summary of Product Characteristics." European Medicines Agency Official product information for bezafibrate across EU member states. Evidence level: Regulatory
- Mach F, Baigent C, Catapano AL, et al. (2020). "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk." European Heart Journal, 41(1), 111-188. https://doi.org/10.1093/eurheartj/ehz455 ESC/EAS clinical guidelines on lipid management including fibrate use. Evidence level: 1A
- The BIP Study Group (2000). "Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study." Circulation, 102(1), 21-27. https://doi.org/10.1161/01.CIR.102.1.21 Landmark randomized controlled trial on bezafibrate for secondary prevention. Evidence level: 1B
- Tenenbaum A, Fisman EZ (2012). "Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction." Cardiovascular Diabetology, 11, 125. https://doi.org/10.1186/1475-2840-11-125 Comprehensive review of fibrate therapy in contemporary dyslipidaemia management. Evidence level: 2A
- National Institute for Health and Care Excellence (NICE). "Cardiovascular disease: risk assessment and reduction, including lipid modification (CG181)." https://www.nice.org.uk/guidance/cg181 UK clinical guideline on cardiovascular risk reduction including fibrate recommendations. Evidence level: 1A
- World Health Organization (WHO). "WHO Model List of Essential Medicines - 23rd List, 2023." WHO Essential Medicines List International reference for essential medicines. Evidence level: Regulatory
- Tenenbaum A, Motro M, Fisman EZ, et al. (2005). "Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome." Archives of Internal Medicine, 165(10), 1154-1160. https://doi.org/10.1001/archinte.165.10.1154 Sub-analysis of BIP trial demonstrating bezafibrate benefit in metabolic syndrome. Evidence level: 1B
Evidence grading: This article uses the GRADE framework for evidence assessment. Level 1A = systematic reviews/meta-analyses of RCTs; Level 1B = individual RCTs; Level 2A = systematic reviews of observational studies; Level 2B = individual observational studies. All sources are peer-reviewed or from established regulatory agencies.